Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosinekinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloidleukemia
Neil P. Shah, John M. Nicoll, Bhushan Nagar, Mercedes E. Gorre, Ronald L. Paquette, John Kuriyan, Charles L. Sawyers
Cancer Cell
Volume 2, Issue 2, Pages 117-125 (August 2002)
DOI: 10.1016/S1535-6108(02)00096-X
Figure 1
Cancer Cell 2002 2, 117-125DOI: (10.1016/S1535-6108(02)00096-X)
Figure 2
Cancer Cell 2002 2, 117-125DOI: (10.1016/S1535-6108(02)00096-X)
Figure 3
Cancer Cell 2002 2, 117-125DOI: (10.1016/S1535-6108(02)00096-X)
Figure 4
Cancer Cell 2002 2, 117-125DOI: (10.1016/S1535-6108(02)00096-X)